WASHINGTON — President Biden is using a Cold War-era law to stem drug shortages by boosting domestic pharmaceutical manufacturing.
Biden announced the initiative at the first meeting of his supply chain resilience council. It’s based on a law, the Defense Production Act, that lets the government require private companies to make materials deemed necessary for national defense, in this case essential medicines and medical countermeasures.
The White House will spend $35 million to boost domestic production of key starting materials for sterile injectables, which are the drugs that hospitals commonly use and are most prone to shortages.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect